Biotechnology Industry 2010 Yearbook - Top Biologics, Biosimilars, Licensing and Financing, Mergers and Acquisitions

Biotechnology Industry 2010 Yearbook - Top Biologics, Biosimilars, Licensing and Financing, Mergers and Acquisitions

Summary

GBI Research, the leading business intelligence provider, has released its latest report, “Biotechnology Industry 2010 Yearbook - Top Biologics, Biosimilars, Licensing and Financing, Mergers and Acquisitions” that provides key data, information and analysis of the major trends and issues affecting the biotech industry. The report provides a comprehensive insight into the biotech industry 2009-2010. The report also provides a detailed analysis of biotech industry market characterization in terms of its market size, segmentation and the major market drivers and barriers. The report also talks about the patent landscape for biotech industry and provides comprehensive analysis. The report also looks into the biotech industry product pipeline along with analysis on the pipeline by indication, phase of development and geography of development. The report also provides competitive landscape of the market that profiles key market players along with their brief business description, pipeline, major products and major M&A and partnership deals.

Scope

The scope of the report includes:

• Detailed overview of biotech industry in 2009-2010
• Key market drivers and restraints,challenges and restraints shaping the biotech industry market
• Pipeline analysis of the biotech industry along with segmentation by indication, phase and geography
• Competitive landscape analysis with competitive profiling of leading companies
• Analysis of M&A deals 2009-2010 along with segmentation by value geography and companies

Reasons to buy

The report will enhance your decision making capability. It will allow you to

• Develop better strategies for biotech industry by understanding the market dynamics of the biotech industry
• Develop market-entry and market expansion strategies by identifying the key areas for high growth and high opportunities
• Understand the factors shaping the biotech industry market
• Identify the key players best positioned to take the advantage of the opportunities in the global biotech industry market
• Exploit partnership and acquisition opportunities by identifying the products that could fill the portfolio gaps

Contents

1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 INTRODUCTION

2.1 GBI Research Report Guidance

3 MARKET CHARACTERIZATION

3.1 Total Revenues for Biologics Sales in 2009
3.2 Drivers and Restraints
  3.2.1 Innovation Gap in Pharmaceutical R&D: Bigger Pharmaceutical Companies are Looking at Biotechnology Innovations to Fill the Gap in Pharmaceutical R&D
  3.2.2 Patent Expiries of Pharmaceutical Blockbusters: Pharmaceutical Companies are Focusing on Biologics due to Lack of Patent Expiry in Recent Years
  3.2.3 Huge Investments in Biotechnology R&D Resulting in Strong Product Pipeline
  3.2.4 Higher Approval Rates for Biotech Products have contributed to Growth of Biotechnology Industry
  3.2.5 High Unmet Needs in Life Threatening Diseases are driving the Biotechnology Market
  3.2.6 Increasing Interest of Pharmaceutical Companies in Biotechnology Industry will Aid the Growth of the Biotechnology Industries
  3.2.7 Strong Growth of Biologics in the Market for Cancer and Autoimmune Diseases
3.3 Restraints
  3.3.1 High Treatment Costs and Low Patient Compliance for Biologics are Slowing down the Market
  3.3.2 Threat from Biosimilars
  3.3.3 Lengthy Approval Process Reduces the Product’s Effective Period of Commercial Success
3.4 Trends
  3.4.1 Development of the Monoclonal Antibodies: Many Biotech Industries are eyeing on Monoclonal Antibodies as High Profit Products
  3.4.2 Biologics for Rheumatoid Arthritis and Cancer: Rheumatoid Arthritis and Cancer are Promising Therapeutic Areas for Biologics
3.5 Challenges
  3.5.1 Challenges in the Biologics Development
  3.5.2 Resources: Lack of Funding Resources has created a Big Challenge for the Biotech Industries
  3.5.3 Compliance Challenge: Complex Regulation and Competition from Biosimilars is Slowing Down the Biotech Market

4 GLOBAL BIOSIMILARS MARKET

4.1 Global Market Size and Forecasts
4.2 The US Biosimilars Market Size and Forecasts
4.3 Europe Biosimilars Market Size and Forecasts
4.4 Japan Biosimilars Size and Market Forecasts
4.5 Market Forecasts for Biosimilars
  4.5.1 Human Growth Hormone Biosimilars Markets
  4.5.2 Erythropoietin Biosimilars Markets
  4.5.3 Granulocyte-Colony Stimulating Factor Biosimilars Markets
4.6 Opportunity Analysis
  4.6.1 Interferon-alpha Biosimilars
  4.6.2 Interferon-Beta Biosimilars
  4.6.3 Insulin and Insulin Analogs Biosimilars
  4.6.4 Monoclonal Antibodies

5 THERAPEUTIC LANDSCAPE

5.1 Total Biologics Revenue by Drug Classes
  5.1.1 Cancer Antibodies
  5.1.2 TNF Alpha Antagonist
  5.1.3 Insulin Products
  5.1.4 Erythropoiesis Stimulating Agents
  5.1.5 Interferon Alpha and Interferon Beta
  5.1.6 Coagulation Factors
  5.1.7 Granulocyte-Colony Stimulating Factor
  5.1.8 Anti-Inflammatory Antibodies
  5.1.9 Human Growth Hormone
  5.1.10 Enzyme Replacement Therapy
  5.1.11 Follicle Stimulating Hormone
  5.1.12 Antibody Products
  5.1.13 Proteins & Peptides

6 TOP 10 BIOTECHNOLOGY COMPANIES

6.1 Roche/Genentech
  6.1.1 Company Overview
  6.1.2 Business Description
  6.1.3 Revenues from Biologics
  6.1.4 Drugs in Pipeline
  6.1.5 Merger & Acquisitions Deals
  6.1.6 Financials
  6.1.7 Ratio Analysis
  6.1.8 SWOT Analysis
6.2 Amgen Inc.
  6.2.1 Company Overview
  6.2.2 Business Description
  6.2.3 Revenues of Biologics
  6.2.4 Drugs in Pipeline
  6.2.5 Merger and Acquisition Deals
  6.2.6 Financials
  6.2.7 Ratio Analysis
  6.2.8 SWOT Analysis
6.3 Novo Nordisk A/S
  6.3.1 Company Overview
  6.3.2 Business Description
  6.3.3 Revenues from Biologicals
  6.3.4 Product Wise Revenue
  6.3.5 Drugs in the Pipeline
  6.3.6 Merger and Acquisition Deals
  6.3.7 Financials
  6.3.8 Ratio Analysis
  6.3.9 SWOT Analysis
6.4 Merck Serono S.A (Merck Serono)
  6.4.1 Company Overview
  6.4.2 Business Overview
  6.4.3 Revenues from Biological
  6.4.4 Drugs in Pipeline
  6.4.5 Merger and Acquisition Deals
  6.4.6 Financials
  6.4.7 Ratio Analysis
  6.4.8 SWOT Analysis
6.5 Baxter International Inc
  6.5.1 Company Overview
  6.5.2 Business Overview
  6.5.3 Revenues from Biologics
  6.5.4 Product Wise Revenue
  6.5.5 Drugs in Pipeline
  6.5.6 Merger & Acquisition Deals
  6.5.7 Financials
  6.5.8 Ratio Analysis
  6.5.9 SWOT Analysis
6.6 Biogen Idec Inc.
  6.6.1 Company Overview
  6.6.2 Business Description
  6.6.3 Product Wise Revenue
  6.6.4 Drugs in Pipeline
  6.6.5 Merger & Acquisition Deals
  6.6.6 Financials
  6.6.7 Ratio Analysis
  6.6.8 SWOT Analysis
6.7 Genzyme Corporation
  6.7.1 Company Overview
  6.7.2 Business Description
  6.7.3 Product Wise Revenue
  6.7.4 Drugs in Pipeline
  6.7.5 Merger & Acquisition Deals
  6.7.6 Financials
  6.7.7 Ratio Analysis
  6.7.8 SWOT Analysis
6.8 CSL Limited
  6.8.1 Introduction
  6.8.2 Business Description
  6.8.3 Revenues from Biologics
  6.8.4 Drugs in Pipeline
  6.8.5 Merger & Acquisition Deals
  6.8.6 Financials
  6.8.7 Ratio Analysis
  6.8.8 SWOT Analysis
6.9 Allergan Inc.
  6.9.1 Companies Overview
  6.9.2 Business Description
  6.9.3 Revenue from Biologics
  6.9.4 Product Wise Revenue
  6.9.5 Drugs in Pipeline
  6.9.6 Merger & Acquisition Deals
  6.9.7 Financials
  6.9.8 Ratio Analysis
  6.9.9 SWOT Analysis
6.10 Alexion Pharmaceutical Inc
  6.10.1 Companies Overview
  6.10.2 Business Overview
  6.10.3 Revenues from Biological
  6.10.4 Product Pipeline
  6.10.5 Merger & Acquisition Deals
  6.10.6 Financials
  6.10.7 Ratio Analysis
  6.10.8 SWOT Analysis

7 SMALL AND MEDIUM SIZE ENTERPRISES

7.1 Biotechnology Clusters and their Role in the Development of Small and Medium Enterprises
  7.1.1 European Biotechnology Industry Clusters
  7.1.2 North American Biotechnology Industry Clusters
7.2 Segmentation of the Biotechnology Industry: Small and Medium Enterprises Dominate
  7.2.1 Segmentation of SMEs by Geography, 2009-2010
  7.2.2 Segmentation of SMEs by Employee Strength (2009-2010)
  7.2.3 Segmentation of SME’s by Therapeutic Area, 2009-2010
7.3 Segmentation of SMEs and Non-SMEs by Biotechnology Drug Pipeline, 2009-2010

8 SMALL AND MEDIUM BIOPHARMACEUTICAL ENTERPRISES – FUNDING SCENARIO

8.1 Small and Medium Enterprise Lifecycle and Sources of Funding
  8.1.1 Pre-Seed and Seed Stage: Angel Investor and Government Grants are the Key Sources of Finance
  8.1.2 Start up Stage: Venture Capital Firms Provide Major Funding
  8.1.3 Early Growth and Expansion Stage: Investments from Big Pharmaceutical and Biotechnology Companies
8.2 Small and Medium Enterprise Funding -Venture Funding, Segmented by Geography
8.3 Small and Medium Size Enterprises M&A Deals
  8.3.1 By Deal Size: The Majority of the Deals were below $20m
  8.3.2 By Geography: The US was the major region of M&A Deals

9 REGULATORY UPDATE FOR THE BIOTECHNOLOGY INDUSTRY,2009-2010

9.1 Regulatory Landscape in the US
  9.1.1 Regulatory Framework for Biopharmaceutical Industry
  9.1.2 Evolution of Regulatory Pathways for Biosimilars
  9.1.3 New Biologics Approvals in the US, 2009-2010
  9.1.4 Recalls, Warnings and Notifications
9.2 Implementation of the Biologics Price Competition and Innovation Act of 2009
  9.2.1 Exclusivity for Reference Product
  9.2.2 Exclusivity for First Interchangeable Biological Product
9.3 Regulatory Landscape in Europe
  9.3.1 Regulatory Framework for Biopharmaceutical Industry in Europe
  9.3.2 New Biologics Approvals in Europe (2009-2010)
  9.3.3 Recalls, Warning and Notifications
9.4 Regulatory Landscape in Japan
  9.4.1 Regulatory Framework for Biopharmaceutical Industry in Japan
  9.4.2 New Biologics Approved in Japan (2009-2010)
  9.4.3 Recalls, Warnings and Notifications

10 M&A DEALS ANALYSIS

10.1 Top 10 Biotechnology Merger & Acquisition
  10.1.1 Segmentation of M&A Deals by Deal Value: Small Biotech Firms Were the Easy Targets for Acquisitions
  10.1.2 Segmentation of M&A Deals by Geography: Majority of Deals Took Place in North America
  10.1.3 Analysis of M&A Trends
  10.1.4 Conclusion

11 BIOTECHNOLOGY INDUSTRY 2010 YEARBOOK – APPENDIX

11.1 Market Definitions
11.2 Abbreviations
11.3 Research Methodology
  11.3.1 Coverage
  11.3.2 Secondary Research
  11.3.3 Primary Research
  11.3.4 Expert Panel Validation
11.4 Contact Us
11.5 Disclaimer
11.6 Sources

LIST OF TABLES

Table 1: Biotechnology Market, Global, Top 10 Biopharmaceutical Companies by Biologics Sales ($bn), 2009
Table 2: Biotechnology Market, Global, Patent Expiry of Top 10 Biologics
Table 3: Biotechnology Market, Global, Top 10 Biologics By Sale Value ($bn), 2008–2009
Table 4: Biotechnology Market, Global, Competitor Products to Aranesp, 2009-2010
Table 5 : Biotechnology Market, The US, Current Biological Product Shortage, 2009-2010
Table 6: Biotechnology Market, Global, List of Approved Biosimilars, 2009
Table 7: Biotechnology Market, Global, Some Approved Biosimilars, Segmented by Geography, 2009
Table 8: Biotechnology Market, Global, Top Five Monoclonal Antibodies by Sales ($bn), 2008–2009
Table 9: Biotechnology Market, Global, Biologics For the Treatment of Rheumatoid Arthritis
Table 10: Biotechnology Market, Global, Biologics For the Treatment of Cancer
Table 11: US Biosimilar Market Forecasts,($m), 2009-2016
Table 12: Europe Biosimilar Market Forecasts,($m),2009
Table 13: Japan Biosimilars Market Forecasts,($m) 2009-2016
Table 14: Global hGH Biosimilars Market Forecasts, ($m), 2009-2016
Table 15: Global, EPO Biosimilars Market Forecasts, ($m),2009-2016
Table 16: Global G-CSF Biosimilars Market Forecasts, ($m), 2009-2016
Table 17: Global, Interferon-Alpha Opportunity Analysis, ($m), 2009-2016
Table 18: Global, Interferon-beta Opportunity Analysis, ($m), 2009-2016
Table 19: Global, Insulin and Insulin Analogs Opportunity Analysis, ($m),2009-2016
Table 20: Biotechnology Market, Top Selling Biologics in Cancer Antibodies - 2009
Table 21: Biotechnology Market, Top Selling Biologics in TNF Antagonist Biologics – 2009
Table 22: Biotechnology Market, Top Selling Insulin Products – 2009
Table 23: Biotechnology Market, Top Selling Biologics in Erythropoiesis Stimulating Agents – 2009
Table 24: Biotechnology Market, Top Selling Biologics in Interferon Alpha - 2009
Table 25: Biotechnology Market, Top Selling Biologics in Interferon-Beta - 2009
Table 26: Biotechnology Market, Top Selling Biologics in Coagulation Factors – 2009
Table 27: Biotechnology Market, Top Selling Biologics in Granulocytes Colony Stimulating Factor – 2009
Table 28: Biotechnology Market, Top Selling Biologics in Anti-inflammatory Antibodies – 2009
Table 29: Biotechnology Market, Top Selling Biologics in Human Growth hormone – 2009
Table 30: Biotechnology Market, Top Selling Biologics in Enzyme Replacement Therapy- 2009
Table 31: Biotechnology Market, Top selling Biologics in Follicle Stimulating Hormone Products – 2009
Table 32: Biotechnology Market, Top Selling Biologics in Antibodies – 2009
Table 33: Biotechnology Market, Top Selling Biologics in Therapeutic Proteins - 2009
Table 34: Biotechnology Market,Top selling Biologics in Therapeutic Peptides – 2009
Table 35: Roche/Genentech. Top Selling Drugs, ($m), 2009
Table 36: Roche – Phase I Product Pipeline, 2010
Table 37: Roche.–.Phase II Product Pipeline ,2010
Table 38: Roche – Phase III Product Pipeline ,2010
Table 39: Roche: Revenue ($bn), 2005-2009
Table 40: Profitability Ratios for Roche. (%), 2005-2009
Table 41: Efficiency Ratios for Roche, 2005-2009
Table 42: Amgen, Revenue from Biologics Sale ($bn),2009
Table 43: Amgen Inc. – Phase I Product Pipeline - 2010
Table 44: Amgen Inc. – Phase II Product Pipeline-2010
Table 45 Amgen Inc. – Phase III Product Pipeline - 2010
Table 46: Amgen Inc., Annual Revenue, ($bn), 2005-2009
Table 47: Profitability Ratios for Amgen Inc., (%), 2005-2009
Table 48: Efficiency Ratios for Amgen Inc., 2005-2009
Table 49: Novo Nordisk ,Total Sale by Segment, ($m),2009
Table 50: Novo Nordisk ,Biopharmaceutical Segment Sale,($m),2009
Table 51: Novo Nordisk ,Diabetic Care Segment Sale, ($m), 2009
Table 52: Diabetic Care Segment Sale- 2009
Table 53: Novo Nordisk – Phase I Product- 2010
Table 54: Novo Nordisk – Phase II Product Pipeline - 2010
Table 55: Novo Nordisk- Phase III Product Pipeline 2010
Table 56: Novo Nordisk, Annual Revenue, ($bn), 2005-2009
Table 57: Profitability Ratios for Novo Nordisk, (%), 2005-2009
Table 58: Novo Nordisk, Efficiency Ratios, 2005-2009
Table 59: Merck Serono Top Selling Drugs – 2009
Table 60: Merck Serono – Phase I Product Pipeline, 2010
Table 61: Merck Serono – Phase II Product Pipeline, 2010
Table 62: Merck Serono – Phase III Product Pipeline, 2010
Table 63: Merck : Annual Revenue, ($bn), 2005-2009
Table 64: Revenue from Business Segment, ($m), 2009
Table 65: Merck Serono,Sale from Pharmaceutical Division ($bn) , 2005-2009
Table 66: Profitability Ratios for Merck : (%), 2005-2009
Table 67: Efficiency Ratios for Merck, 2005-2009
Table 68: Baxter Biosciencies, Summary Of The Sale By Product ($m), 2008-2009
Table 69: Baxter Biosciencies, Sales from Medication Delivery Segment ,2008 & 2009
Table 70: Baxter Biosciences - Phase-II Product Pipeline,2010
Table 71: Baxter Biosciences – Phase III Clinical Pipeline, 2010
Table 72: Baxter Inc., Annual Revenue, ($bn), 2005-2009
Table 73: Baxter Inc. : Sale by Segment,2008 & 2009
Table 74: Profitability Ratios for Baxter Inc., (%), 2005-2009
Table 75: Efficiency Ratios for Baxter Inc., 2005-2009
Table 76: Biogen Idec Inc. Product wise Revenue, ($m), 2009
Table 77: Biogen Idec Inc. – Phase II Product Pipeline 2010
Table 78: Biogen Idec Inc. – Phase II Product Pipeline, 2010
Table 79: Biogen Idec Inc. – Phase III Product Pipeline, 2010
Table 80: Biogen Idec Inc., Annual Revenue, ($bn), 2005-2009
Table 81: Profitability Ratios for Biogen Idec Inc., (%), 2005-2009
Table 82: Efficiency Ratios for Biogen Idec Inc., 2005-2009
Table 83: Genzyme ,Top Selling Drug,($m), 2009
Table 84: Genzyme – Phase I Product Pipeline 2010
Table 85: Genzyme – Phase II Product Pipeline 2010
Table 86: Genzyme – Phase III Product Pipeline 2010
Table 87: Genzyme., Annual Revenue, ($bn), 2005-2009
Table 88: Genzyme., Profitability Ratios, (%), 2005-2009
Table 89: Genzyme, Efficiency Ratios ., 2005-2009
Table 90: Revenue from Biologics - 2010
Table 91: CSL Ltd.- Phase I Product Pipeline 2010
Table 92: CSL Ltd.- Phase II Product Pipeline 2010
Table 93: CSL Ltd.- Phase III Product Pipeline 2010
Table 94: CSL Ltd. Annual Revenue, ($bn), 2006-2009
Table 95: Profitability Ratios for CSL Ltd. (%), 2006-2010
Table 96: Efficiency Ratios for CSL Ltd., 2006-2010
Table 97: Allergan Inc,Total Product Sale,($m),2009
Table 98: Allergan Inc,Total Medical Devices Sale,($m),2009
Table 99: Allergan Inc. – Phase I Product Pipeline, 2010
Table 100: Allergan Inc. – Phase II Product Pipeline, 2010
Table 101: Allergan Inc. – Phase III Product Pipeline,2010
Table 102: Allergan Inc. Annual Revenue, ($bn), 2005-2009
Table 103: Profitability Ratios for Allergan Inc., (%), 2005-2009
Table 104: Efficiency Ratios for Allergan Inc., 2005-2009
Table 105: Alexion Pharmaceutical Inc. – Phase I Product Pipeline, 2010
Table 106: Alexion Pharmaceutical Inc.- Phase I product Pipeline 2010
Table 107: Alexion Pharmaceuticals Inc., Historical Revenue, ($m), 2005-2009
Table 108: Alexion Pharmaceuticals Inc., Net Income and R&D Expense, ($m), 2007-2009
Table 109: Profitability Ratios for Alexion Pharmaceuticals Inc., (%), 2005-2009
Table 110: Efficiency Ratios for Alexion Pharmaceuticals Inc., 2005-2009
Table 111: Country Break-up of Healthcare Biotechnology SMEs in North America and Europe, 2009
Table 112: Biologics Licensee Approval in the US , 2009
Table 113: New Biologics Approved in Europe 2009
Table 114: Biosimilars Approved in Europe ,2006-2009
Table 115: Applications Rejected or Withdrawn in Europe,2006-2009
Table 116: Biologics Approved In Japan 2009-2010
Table 117: Top 10 M&A Deal By Deal Value,($m), 2009

LIST OF FIGURES

Figure 1: Biotechnology Market, Global, Sales of Top 10 Biologics ($bn), 2008–2009
Figure 2: Biotechnology Market, Global, Drivers and Restraints to Growth, 2009-2010
Figure 3: Biosimilar Market, The US, The Future of Biosimilars, Revenue Forecasts ($m), 2009-2016
figure 4: Biosimilar Market ,The Future of Biosimilars, Europe, Market Forecasts,($m) 2009-2016
Figure 5: Biosimilar Market, The Future of Biosimilars, Japan, Market Forecasts, ($m), 2009-2016
Figure 6: Biosimilar Market, Global hGH Biosimilars Market Forecasts, ($m) 2009- 2016
Figure 7: Biosimilar Market, Global, Erythropoietin Biosimilars Market Forecasts, ($m) 2009-2016
Figure 8: Biosimilar Market, Global, G-CSF Biosimilars Market Forecasts, ($m) 2009-2016
Figure 9: Biosimilar Market, Global, Interferon-alpha Opportunity Analysis, ($m) 2009-2016
Figure 10: BIosimilar Market, Global Interferon-beta Opportunity Analysis, ($m), 2009-2016
Figure 11: Biosimilar Market, Global, Insulin and Insulin Analogs Opportunity Analysis, ($m), 2009-2016
Figure 12: Biotechnology Market, Global Biologics Sale by Drug Classes,2009-2010
Figure 13: Roche:Annual Revenue, ($bn), 2005-2009
Figure 14: SWOT Analysis of Roche/Genentech
Figure 15: Amgen, Product wise Sale-2009
Figure 16: Amgen Inc. Annual Revenue, ($bn), 2005-2009
Figure 17: SWOT Analysis of Amgen Inc.
Figure 18: Novo Nordisk, Total Sale By Segment - 2009
Figure 19: Novo Nordisk ,Sale of Biopharmaceutical Segment
Figure 20: Novo Nordisk ,Sale from the Diabetic Care Segment ,2009
Figure 21: Novo Nordisk. Annual Revenue, ($bn),2005-2009
Figure 22: SWOT Analysis of Novo Nordisk
Figure 23: Merck Serono - Top 5 Medicines by Sale- 2009
Figure 24: Merck Serono - Sale By Region
Figure 25: Merck: Annual Revenue, ($bn), 2005-2009
Figure 26: Merck Serono,Revenue from Business Segment,2009
Figure 27: Merck Serono,Pharmaceutical Revenue ,($bn), 2005-2009
Figure 28: SWOT Analysis of Merck Serono
Figure 29: Baxter Biosciencies, Sale by Product – 2009
Figure 30: Baxter Biosciencies, Sale By Business Segment, 2009
Figure 31: Baxter Inc. Annual Revenue,2005-2009
Figure 32: SWOT Analysis of Baxter
Figure 33: Biogen Idec, Product wise Revenue – 2009
Figure 34: Biogen Idec Inc. Annual Revenue, ($bn), 2005-2009
Figure 35: SWOT Analysis of Biogen Idec
Figure 36: Genzyme: Revenue by Business Group,2009
Figure 37: Genzyme ,Top Selling Drugs-2009
Figure 38: Genzyme, Annual Revenue,($bn), 2005-2009
Figure 39: SWOT Analysis of Genzyme
Figure 40: CSL Ltd, Sale of biologics in Fiscal Year - 2009
Figure 41: CSL Ltd. Annual Revenue, ($bn), 2005-2009
Figure 42: SWOT Analysis of CSL Limited
Figure 43: Allergan Inc,Total Pharmaceutical Sale,2009
Figure 44: Allergan Inc,Total Medical Device Sale- 2009
Figure 45: Allergan Inc. Annual Revenue, ($bn), 2005-2009
Figure 46: SWOT Analysis of Allergan Inc
Figure 47: Alexion Pharmaceuticals Inc. Annual Revenue,($m), 2005-2009
Figure 48: SWOT Analysis of Alexion
Figure 49: Key Biotechnology Clusters in Europe, 2010
Figure 50: Key Biotechnology Clusters in the US, 2010
Figure 51: Key Biotechnology Clusters in Canada, 2010
Figure 52: Composition of the European and North American Biotechnology Industry, Number of SMEs 2009
Figure 53: Composition of the European and North American Biotechnology Industry, 2009
Figure 54: Segmentation of SMEs by Geography, 2009
Figure 55: Break-up of SME Sector by Country, 2009
Figure 56: SMEs Segmented by Size, 2009
Figure 57: Number of SMEs by Therapeutic Areas, 2009
Figure 58: Therapeutics Areas of Focus for SMEs, 2009
Figure 59: Segmentation of Pipeline Products across SMEs and Non-SMEs, 2009
Figure 60: SME Lifecycle and Sources of Funding Value ($m),2009
Figure 61: Number of SME VC Deals by Region, ($bn), 2009-2010
Figure 62: Segmentation of SMEs M&A Deals by Value ($m),2009-2010
Figure 63: Segmentation of M&A Deals for SME’s by Geography , 2009-2010
Figure 64: The Future of Biosimilars, US, Regulatory Bodies for Biologics, November 2009
Figure 65: US, Drug Development and Approval Process
Figure 66: The Future of Biosimilars, US, Impact of Data Exclusivity Period on Biosimilars Development
Figure 67: Drug Approval Process in Europe
Figure 68: Number of Biosimilar Applications in Europe,2005-2009
Figure 69: Evolution of Regulatory Pathway in Japan,2006-2009
Figure 70: Segmentation of M&A Deals by Value ($bn), 2009-2010
Figure 71: Segmentation of M&A Deals By Geography,2009 Skip to top